Fresenius Kabi AB — China drug registrations and re-registration deadlines
22 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2028-01-02.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20130852 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130853 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130854 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130855 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130856 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130857 | Kabiven 脂肪乳氨基酸(17)葡萄糖(19%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130922 | Kabiven PI 脂肪乳氨基酸(17)葡萄糖(11%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130923 | Kabiven PI 脂肪乳氨基酸(17)葡萄糖(11%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130924 | Kabiven PI 脂肪乳氨基酸(17)葡萄糖(11%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130925 | Kabiven PI 脂肪乳氨基酸(17)葡萄糖(11%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20130926 | Kabiven PI 脂肪乳氨基酸(17)葡萄糖(11%)注射液 | 2028-07-02 | 2028-01-02 |
| 国药准字HJ20160018 | Structolipid 结构脂肪乳注射液(C6~24) | 2029-09-24 | 2029-03-24 |
| 国药准字HJ20160019 | Structolipid 结构脂肪乳注射液(C6~24) | 2029-09-24 | 2029-03-24 |
| 国药准字HJ20160020 | Structolipid 结构脂肪乳注射液(C6~24) | 2029-09-24 | 2029-03-24 |
| 国药准字HJ20160021 | Structolipid 结构脂肪乳注射液(C6~24) | 2029-09-24 | 2029-03-24 |
| 国药准字HJ20240106 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (42%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（42%）注射液 | 2029-10-15 | 2029-04-15 |
| 国药准字HJ20240107 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (42%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（42%）注射液 | 2029-10-15 | 2029-04-15 |
| 国药准字HJ20240108 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (42%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（42%）注射液 | 2029-10-15 | 2029-04-15 |
| 国药准字HJ20240109 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (42%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（42%）注射液 | 2029-10-15 | 2029-04-15 |
| 国药准字HJ20240150 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (13%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（13%）注射液 | 2029-11-30 | 2029-05-30 |
| 国药准字HJ20240151 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (13%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（13%）注射液 | 2029-11-30 | 2029-05-30 |
| 国药准字HJ20240152 | Fish Oil (3%) Olive Oil Medium and Long Chain Fat Emulsion/Amino Acids (16)/ Glucose (13%) Injection 鱼油（3%）橄榄油中/长链脂肪乳/氨基酸（16）/葡萄糖（13%）注射液 | 2029-11-30 | 2029-05-30 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.